Sarepta Posts $1.86B in 2025 Revenue, ELEVIDYS Sales Impacted by Flu Season
Event summary
- Sarepta Therapeutics reported preliminary net product revenues of $369.6 million for Q4 2025 and $1.86 billion for full-year 2025.
- ELEVIDYS generated $110.4 million in Q4 2025 revenue and $898.7 million for the full year, impacted by rescheduling of patient infusions.
- The PMO franchise contributed $259.2 million in Q4 2025 and $965.6 million for the full year.
- As of December 31, 2025, Sarepta held approximately $953.8 million in cash, cash equivalents, restricted cash, and investments.
The big picture
Sarepta's strong revenue performance underscores the growing market for precision genetic medicine targeting rare diseases. The company's reliance on ELEVIDYS, while generating significant revenue, also exposes it to regulatory and safety risks that could impact future growth. The company's cash position provides flexibility to invest in its pipeline, but continued success will depend on navigating these challenges and demonstrating the value of its therapies.
What we're watching
- Sales Execution
- Sarepta's ability to exceed its $500 million annual sales floor for ELEVIDYS will hinge on the success of planned initiatives, and the company’s lack of detailed guidance suggests uncertainty around their impact.
- Regulatory Risk
- The FDA’s ongoing scrutiny of gene therapies, particularly regarding liver safety concerns associated with ELEVIDYS, could lead to further restrictions or labeling changes impacting adoption.
- Pipeline Progress
- The advancement of Sarepta’s siRNA pipeline will be critical for long-term growth, and the company’s financial strength will determine the pace and scope of its development efforts.
Related topics